Patents by Inventor Luca Tamagnone

Luca Tamagnone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Non-natural Semaphorins 3 and their medical use
    Patent number: 10906948
    Abstract: The present invention relates to non-naturally occurring, mutated Semaphorin 3 molecules. Particularly, the invention relates to the mutated Semaphorin 3 or the functional fragment thereof that exhibit improved properties and pharmacologic effects, e.g., in the treatment of angiogenic disease and cancer. In addition, the present invention relates to nucleic acid molecules encoding such polypeptides, and vectors and hosts comprising such nucleic acids. The invention further relates to methods for producing the polypeptides of the invention, and to methods of using them in the treatment of disease, in particular in the medical intervention of angiogenic diseases, tumors and/or cancer.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: February 2, 2021
    Assignee: Seagull Therapeutics SAS
    Inventors: Guido Serini, Enrico Giraudo, Luca Tamagnone
  • NON-NATURAL SEMAPHORINS 3 AND THEIR MEDICAL USE
    Publication number: 20180030100
    Abstract: The present invention relates to non-naturally occurring, mutated Semaphorin 3 molecules. Particularly, the invention relates to the mutated Semaphorin 3 or the functional fragment thereof that exhibit improved properties and pharmacologic effects, e.g., in the treatment of angiogenic disease and cancer. In addition, the present invention relates to nucleic acid molecules encoding such polypeptides, and vectors and hosts comprising such nucleic acids. The invention further relates to methods for producing the polypeptides of the invention, and to methods of using them in the treatment of disease, in particular in the medical intervention of angiogenic diseases, tumors and/or cancer.
    Type: Application
    Filed: February 23, 2016
    Publication date: February 1, 2018
    Applicant: Seagull Therapeutics SAS
    Inventors: Guido Serini, Enrico Giraudo, Luca Tamagnone
  • Regulation of vascular endothelium using BMX tyrosine kinase
    Publication number: 20060160761
    Abstract: Vascular endothelia are subject to atherosclerotic and arteriostenotic effects transduced by molecules, such as thrombin, IL-3 and VEGF which can lead to vessel occlusion or stenosis. An endothelial signaling pathway involving the Bmx tyrosine kinase contributes to normal endothelial nonthrombogenic, inflammatory and growth conditions of arterial vessels, and regulation of the pathway can treat or prevent pathological conditions in the vessel walls.
    Type: Application
    Filed: December 14, 2005
    Publication date: July 20, 2006
    Inventors: Niklas Ekman, Elena Arighi, Imre Vastrik, Luca Tamagnone, Kari Alitalo
  • Regulation of vascular endothelium using BMX tyrosine kinase
    Publication number: 20020173481
    Abstract: Vascular endothelia are subject to atherosclerotic and arteriostenotic effects transduced by molecules, such as thrombin, IL-3 and VEGF which can lead to vessel occlusion or stenosis. An endothelial signaling pathway involving the Bmx tyrosine kinase contributes to normal endothelial nonthrombogenic, inflammatory and growth conditions of arterial vessels, and regulation of the pathway can treat or prevent pathological conditions in the vessel walls.
    Type: Application
    Filed: July 1, 2002
    Publication date: November 21, 2002
    Inventors: Niklas Ekman, Elena Arighi, Imre Vastrik, Luca Tamagnone, Kari Alitalo